Tris Pharma

查看带有其 17 名主要高管的组织结构图

Tris Pharma 搜索最多的简介

• Ketan Mehta, Chief Executive Officer and President
• Peter Ciano, Chief Financial Officer and Senior Vice President, Co...
• Cheryl Patnick, Senior Vice President, Human Resources and Adminis...

高管在Tris Pharma变化

• Manesh Naidu 曾任 Vice President, Marketing, 现升职为 Chief Commercial Officer  (新闻发布的2024九月17号).

创建提醒
跟踪 Tris Pharma 的高管变动

Tris Pharma 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Stemtech and Seacret Direct have announced they will merge  (公布2024十二月5号)..
• Recursion Pharma and Exscientia have merged  (公布2024十一月27号)..
• Stemtech and Seacret Direct have announced they will merge  (公布2024十一月22号)..

药店 行业的其他推荐联系人

• Adare Pharmaceuticals 企业 Kristin Berkinsky - Chief Human Resources Officer
• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board

了解更多有关药店行业的信息 >

Tris Pharma 的最新新闻稿

• Media Highlights and Coverage | Tris Pharma
• Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
• Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
• Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
• Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
• Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
• Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
• Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
• Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
• Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
• View more press releases Close

关于 Tris Pharma 的社交媒体

• Tris Pharma 在 维基百科、谷歌新闻 和 雅虎财经
• Tris Pharma 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Ketan Mehta

致电Tris Pharma，电话：+1 732...

查看组织结构图

Register to receive your alert

报告错误